ei ole lubatud
ei ole lubatud
Digitaalõiguste kaitse (DRM)
Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).
Vajalik tarkvara
Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)
PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )
Seda e-raamatut ei saa lugeda Amazon Kindle's.
Part I Diagnosis.- 1 Classification of adenocarcinoma of the lung - with a special reference to prognosis .- 2 Screening lung cancer with low dose CT combined with molecular markers.- 3 PET-CT, bio-imaging for predicting prognosis and response to chemotherapy in patients with lung cancer.- 4 Methods in molecular diagnosis.- 5 Accurate nodal staging and biomarker testing with endobronchial ultrasound-guided transbronchial needle aspiration.- 6 Next generation sequencing and bioinformatics.- 7 Companion Diagnostics.- Part II Treatment.- 8 Small cell lung cancer and molecular targeted therapy.- 9 Locally advanced non-small cell lung cancer and molecular targeted therapy.- 10 EGFR mutant.- 11 ALK mutant.- 12 Minor-driver mutant.- 13 Mechanism of resistance to targeted molecular therapy.- 14 Immunotherapy.- 15 Lung cancer complicated with interstitial lung diseases.- 16 Management of adverse effects by molecular targeted therapy and immunotherapy.- Part III Evaluation.- 17 Health related-quality of life in molecular targeted therapy.- 18 Gene signature.- Part IV Novel approach.- 19 Targeting epithelial-mesenchymal transition and cancer stem cell- 20 Targeting the Lung Cancer Microenvironment: Harnessing Host Responses.